Article
Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.
International journal of radiation oncology, biology, physics - 15 Mar 2025
Keane Florence K, Yeap Beow Y, Khandekar Melin J, Lin Jessica J, Dagogo-Jack Ibiayi, Sequist Lecia V, Piotrowska Zofia, Willers Henning
Abstract excerpt
PURPOSE: The role of stereotactic body radiation therapy (SBRT) in the management of advanced EGFR/ALK/ROS1-driven non-small cell lung carcinoma (NSCLC) remains undefined. In EGFR-mutant NSCLC, 50-60% of recurrences on first-line tyrosine kinase inhibitors (TKIs) occur in originally involved sites and may lead to subsequent distant failures (DFs). We sought to determine whether consolidative SBRT to residual...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.